Back to Journals » Lung Cancer: Targets and Therapy » Volume 9

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

Total article views   HTML views PDF downloads Totals
7,779 Dovepress* 6,523+ 989 7,512
PubMed Central* 1,256 197 1,453
Totals 7,779 1,186 8,965
*Since 8 November 2018

View citations on PubMed Central and Google Scholar